With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?

If the science behind a drug shows it to be rationally targeted at a cancer-causing genetic mutation, and if early clinical trials show the drug is safe and happens to be especially effective, should the drug be held to the same time-consuming and expensive testing standards of traditional chemotherapies? Or is the clinical trials process a relic from the time of earlier, highly toxic therapies?

Fuente : http://www.eurekalert.org/pub_releases/2013-08/uoc…



Hacer un comentario